{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:50:04Z","timestamp":1778694604141,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202108440074"],"award-info":[{"award-number":["202108440074"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["468853597"],"award-info":[{"award-number":["468853597"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82161138021"],"award-info":[{"award-number":["82161138021"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.schres.2024.10.016","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T10:41:32Z","timestamp":1730112092000},"page":"360-373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Efficacy and tolerability of blonanserin in schizophrenia: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"274","author":[{"given":"Jing","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimeng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridon","family":"Siafis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengchang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Yanagimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2024.10.016_bb0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid. Based Ment. Health"},{"key":"10.1016\/j.schres.2024.10.016_bb0010","series-title":"A Comparative Study of Efficacy of Blonanserin Versus Risperidone in Schizophrenia. PMCID: PMC9045590. G. ACHARI PRIZE SESSION: ORAL PRESENTATION., 2021 Dec","author":"Choudhary","year":"2021"},{"key":"10.1016\/j.schres.2024.10.016_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.00632","article-title":"Negative symptoms of schizophrenia and dopaminergic transmission: translational models and perspectives opened by iPSC techniques","volume":"14","author":"Collo","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.schres.2024.10.016_bb0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11202620-000000000-00000","article-title":"Blonanserin: a review of its use in the management of schizophrenia","volume":"24","author":"Deeks","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2024.10.016_bb0025","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.4 (updated August 2023)","article-title":"Chapter 10: Analysing data and undertaking meta-analyses","author":"Deeks","year":"2023"},{"key":"10.1016\/j.schres.2024.10.016_bb0030","first-page":"FC07","article-title":"Clinical assessment of weight gain with atypical antipsychotics-Blonanserin vs amisulpride","volume":"9","author":"Deepak","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.schres.2024.10.016_bb0035","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"bmj"},{"key":"10.1016\/j.schres.2024.10.016_bb0040","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","article-title":"The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study","volume":"23","author":"Garcia","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2024.10.016_bb0045","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1093\/schbul\/sbx199","article-title":"The circuitry of dopamine system regulation and its disruption in schizophrenia: insights into treatment and prevention","volume":"45","author":"Grace","year":"2019","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2024.10.016_bb0050","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"bmj"},{"key":"10.1016\/j.schres.2024.10.016_bb0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/npr2.12057","article-title":"Blonanserin versus haloperidol in Japanese patients with schizophrenia: a phase 3, 8-week, double-blind, multicenter, randomized controlled study","volume":"39","author":"Harvey","year":"2019","journal-title":"Neuropsychopharmacology reports"},{"key":"10.1016\/j.schres.2024.10.016_bb0060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/npr2.12089","article-title":"Blonanserin vs risperidone in Japanese patients with schizophrenia: a post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study","volume":"40","author":"Harvey","year":"2020","journal-title":"Neuropsychopharmacology reports"},{"key":"10.1016\/j.schres.2024.10.016_bb0065","author":"Higgins"},{"key":"10.1016\/j.schres.2024.10.016_bb0070","author":"Higgins"},{"key":"10.1016\/j.schres.2024.10.016_bb0075","author":"Higgins"},{"key":"10.1016\/j.schres.2024.10.016_bb0080","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bbr.2013.03.027","article-title":"Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: role of indirect 5-HT1A partial agonism","volume":"247","author":"Horiguchi","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.schres.2024.10.016_bb0085","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"The Lancet"},{"key":"10.1016\/j.schres.2024.10.016_bb0090","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jphs.2020.09.006","article-title":"Safety and effectiveness of oral blonanserin for schizophrenia: a review of Japanese post-marketing surveillances","volume":"145","author":"Inoue","year":"2021","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.schres.2024.10.016_bb0095","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/pcn.13304","article-title":"Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study","volume":"76","author":"Ishigooka","year":"2022","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.schres.2024.10.016_bb0100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s40263-019-00692-6","article-title":"Long-term safety and efficacy of blonanserin transdermal patches in Japanese patients with schizophrenia: a 52-week open-label, multicenter study","volume":"34","author":"Iwata","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2024.10.016_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.67","article-title":"Schizophrenia (Primer)","volume":"1","author":"Kahn","year":"2015","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.schres.2024.10.016_bb0110","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5234\/cnpt.8.16","article-title":"A 52-week, randomized, open-label study of aripiprazole versus blonanserin in the treatment of Japanese schizophrenia patients","volume":"8","author":"Katsuki","year":"2017","journal-title":"Clinical Neuropsychopharmacology and Therapeutics"},{"key":"10.1016\/j.schres.2024.10.016_bb0115","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jpsychires.2012.10.011","article-title":"Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials","volume":"47","author":"Kishi","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2024.10.016_bb0120","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.2147\/NDT.S121588","article-title":"A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders","author":"Kishi","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2024.10.016_bb0125","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/a-0574-0088","article-title":"Efficacy, tolerability, and safety of blonanserin in schizophrenia: an updated and extended systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Kishi","year":"2019","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.schres.2024.10.016_bb0130","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jpsychires.2021.04.032","article-title":"Efficacy and safety of antipsychotic treatments for schizophrenia: a systematic review and network meta-analysis of randomized trials in Japan","volume":"138","author":"Kishi","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2024.10.016_bb0135","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.schres.2022.01.001","article-title":"About the issue of including or excluding studies from China in systematic reviews","volume":"240","author":"Leucht","year":"2022","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2024.10.016_bb0140","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpsychires.2015.07.015","article-title":"Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: a double-blind, parallel-group multicenter randomized trial","volume":"69","author":"Li","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2024.10.016_bb0145","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.schres.2024.10.016_bb0150","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1177\/02698811231205688","article-title":"Second international consensus study of antipsychotic dosing (ICSAD-2)","volume":"37","author":"McAdam","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.10.016_bb0160","article-title":"AD-5423 versus haloperidol in the treatment of schizophrenic patients: results of the Japan multicentre, double-blind trial","volume":"268","author":"Murasaki","year":"2002","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2024.10.016_bb0165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/cap.2021.0013","article-title":"Efficacy and safety of blonanserin oral tablet in adolescents with schizophrenia: a 6-week, randomized placebo-controlled study","volume":"32","author":"Saito","year":"2022","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.schres.2024.10.016_bb0170","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00213-020-05698-3","article-title":"Evaluation of dopamine D 3 receptor occupancy by blonanserin using [11 C]-(+)-PHNO in schizophrenia patients","volume":"238","author":"Sakayori","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.schres.2024.10.016_bb0175","first-page":"S469","year":"2013","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2024.10.016_bb0180","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","article-title":"Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis","volume":"399","author":"Schneider-Thoma","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2024.10.016_bb0185","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.biopsych.2013.11.023","article-title":"Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition","volume":"76","author":"Simpson","year":"2014","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2024.10.016_bb0190","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"bmj"},{"key":"10.1016\/j.schres.2024.10.016_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2288-14-30","article-title":"Which is more generalizable, powerful and interpretable in meta-analyses, mean difference or standardized mean difference?","volume":"14","author":"Takeshima","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.schres.2024.10.016_bb0200","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/NDT.S34433","article-title":"Profile of blonanserin for the treatment of schizophrenia","author":"Tenjin","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2024.10.016_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12874-018-0554-2","article-title":"Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.schres.2024.10.016_bb0210","series-title":"Comparison of drug attitude and adherence between blonanserin and risperidone in patients with schizophrenia","year":"2015"},{"key":"10.1016\/j.schres.2024.10.016_bb0215","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/WNF.0b013e3181dcda50","article-title":"Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial","volume":"33","author":"Yang","year":"2010","journal-title":"Clin. Neuropharmacol."}],"updated-by":[{"DOI":"10.1016\/j.schres.2025.03.035","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000}}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424004584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996424004584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T20:43:52Z","timestamp":1763757832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996424004584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":42,"alternative-id":["S0920996424004584"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2024.10.016","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of blonanserin in schizophrenia: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2024.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}